期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
Fe_(25)Co_(25)Pt_(25)B_(25)高熵纳米复相永磁体的组织结构与磁性能
1
作者 贾雨桐 薛钧升 +2 位作者 李艳辉 马殿国 张伟 《材料热处理学报》 CAS CSCD 北大核心 2024年第3期22-28,共7页
采用液态急冷法制备了高熵Fe_(25)Co_(25)Pt_(25)B_(25)合金,研究了其热处理前后的组织结构及磁性能。结果表明:Fe_(25)Co_(25)Pt_(25)B_(25)高熵合金具有较高的非晶形成能力,液态急冷合金形成了非晶态结构,表现出软磁特性。Fe_(25)Co_(... 采用液态急冷法制备了高熵Fe_(25)Co_(25)Pt_(25)B_(25)合金,研究了其热处理前后的组织结构及磁性能。结果表明:Fe_(25)Co_(25)Pt_(25)B_(25)高熵合金具有较高的非晶形成能力,液态急冷合金形成了非晶态结构,表现出软磁特性。Fe_(25)Co_(25)Pt_(25)B_(25)高熵非晶合金热处理结晶化过程为:非晶相→非晶相+fcc-(Fe,Co)Pt相→非晶相+fcc-(Fe,Co)Pt+L1_(0)-(Fe,Co)Pt+(Fe,Co)2B相→非晶相+L1_(0)-(Fe,Co)Pt+(Fe,Co)2B相→L1_(0)-(Fe,Co)Pt+(Fe,Co)2B相。经843 K热处理900 s后,Fe_(25)Co_(25)Pt_(25)B_(25)合金形成了由有序面心四方结构的永磁L1_(0)-(Fe,Co)Pt相和软磁(Fe,Co)2B相组成的纳米复相组织,平均晶粒尺寸约为19 nm,表现出纳米复相永磁体特性,其矫顽力(iHc)、剩磁(Br)、剩磁比(Mr/Ms)和磁能积((BH)_(max))分别为946.8 kA·m^(-1)、0.46 T、0.78和40.9 kJ·m^(-3)。其超大iHc主要是高熵化使L10相的c/a增大导致磁晶各向异性增大的结果。 展开更多
关键词 FeCoPtB高熵合金 纳米复相永磁体 非晶态合金 结晶化 矫顽力
原文传递
《基于药代动力学方法支持PD-1/PD-L1单抗治疗肿瘤患者的替代剂量方案选择指南》解读 被引量:2
2
作者 刘维 薛钧升 +3 位作者 于之恒 王紫愉 陈镕 周田彦 《中国临床药理学与治疗学》 CAS CSCD 2022年第1期86-94,共9页
近年来,以定量药理学为基础的模型化与仿真技术在新药研发中的地位日益凸显。2021年8月,FDA发布了《基于药代动力学方法支持PD-1/PD-L1单抗治疗肿瘤患者的替代剂量方案选择指南》征求意见稿(以下简称"《指南》"),提出基于群体... 近年来,以定量药理学为基础的模型化与仿真技术在新药研发中的地位日益凸显。2021年8月,FDA发布了《基于药代动力学方法支持PD-1/PD-L1单抗治疗肿瘤患者的替代剂量方案选择指南》征求意见稿(以下简称"《指南》"),提出基于群体PK(Pop-PK)模型仿真寻找替代方案的必要性和具体实施标准。本文首先对PD-1/PD-L1单抗的现有临床方案以及该指南的内容进行了总结,随后列举了基于Pop-PK仿真方法辅助替代方案获批的既往实际案例,并进一步分析了该指南用于PD-1/PD-L1单抗替代方案优化的要点,展望其对PD-1/PD-L1单抗临床研发的意义和价值,以期为国内同行提供参考。 展开更多
关键词 定量药理学 群体PK 模型仿真 模型引导的药物研发
在线阅读 下载PDF
化合物C17通过抑制肿瘤干细胞抗胰腺癌的药效学及机制研究 被引量:1
3
作者 薛钧升 冯瑶瑶 +3 位作者 焦佩丽 严晓雪 陈国术 周田彦 《药学学报》 CAS CSCD 北大核心 2020年第10期2381-2391,共11页
C17是一种包含2,4-二氨基喹唑啉和芳基哌嗪的小分子化合物。本研究首先利用分子对接(docking)考察C17与多巴胺D1受体(D1 dopamine receptor,D1DR)等5种DR亚型的结合情况,结果显示,在5个DR亚型中,C17最有可能与D1DR结合。随后采用胰腺癌... C17是一种包含2,4-二氨基喹唑啉和芳基哌嗪的小分子化合物。本研究首先利用分子对接(docking)考察C17与多巴胺D1受体(D1 dopamine receptor,D1DR)等5种DR亚型的结合情况,结果显示,在5个DR亚型中,C17最有可能与D1DR结合。随后采用胰腺癌细胞SW1990及PANC-1进行体内外实验:免疫荧光结果显示,C17可上调两种细胞中的D1DR表达;由细胞毒实验可知C17对SW1990、PANC-1细胞的IC50值分别为12.56和10.56μmol·L-1;克隆形成实验显示C17可以剂量依赖性地抑制两种细胞的克隆形成能力;分别采用CD133和ALDH标记SW1990和PANC-1细胞中肿瘤干细胞(cancer stem-like cell,CSC)亚群,并用流式细胞术证明C17可剂量依赖性地抑制两种细胞的CSC比例;将C17预处理的SW1990细胞接种至nu/nu裸鼠体内,结果显示C17可抑制其体内致瘤性,且与CSC比例相关;进一步体内实验显示,C17单用及与舒尼替尼(sunitinib,SUN)联用具有良好的体内药效和安全性。所有动物实验均严格遵循北京大学生物医学伦理委员会的规定。上述结果提示,C17可能具有用于胰腺癌治疗的潜力。 展开更多
关键词 胰腺癌 肿瘤干细胞 多巴胺D1受体 C17 舒尼替尼
原文传递
A highly sensitive LC-MS/MS method for the determination of 21-hydroxy deflazacort in nude mice plasma and its application to a pharmacokinetic study
4
作者 姚庆宇 李健 +7 位作者 姚烨 陈镕 陈文君 苏红 杨亮 薛钧升 卢炜 周田彦 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2017年第6期404-412,共9页
In the current study, we established and validated a simple and sensitive liquid chromatography-tandem mass spectrometric method for the determination of 21-hydroxy deflazacort in nude mice plasma, and such a method w... In the current study, we established and validated a simple and sensitive liquid chromatography-tandem mass spectrometric method for the determination of 21-hydroxy deflazacort in nude mice plasma, and such a method was applied to a pharmacokinetic study. Using betamethasone as the internal standard, the plasma samples were pre-treated by precipitation with acetonitrile and then analyzed on a reversed-phase C18 column (50 mm×2 mm, 5 μm) with a mobile phase consisting of acetonitrile and 4.0 mM ammonium formate (pH was adjusted to 3.5 with formic acid (40:60, v/v)). The analyte was detected by a triple quadrupole tandem mass spectrometer using electrospray, and multiple reaction monitoring was employed to select 21-hydroxy deflazacort at m/z 400.2/124.0 and betamethasone at m/z 393.3/147.0 in the positive ion mode. The calibration curves were linear (r〉0.99) over the range of 0.5~,00 ng/mL. The intra- and inter-day precisions and accuracies were 4.5%-10.1% and -1.7%-10.7% respectively. This method was successfully applied to a preclinical administered with a single oral dose of 4 mg/kg deflazacort, and its pharmacokinetic study of deflazacort on female nude mice pharmacokinetics was characterized by a two-compartment model with first-order absorption. 展开更多
关键词 DEFLAZACORT 21-Hydorxy deflazacort LC-MS/MS Nude mice PHARMACOKINETICS
原文传递
药动学/药效学模型研究抗CD3/EpCAM双特异性抗体M701在人结肠癌异种移植小鼠中的抗肿瘤作用
5
作者 宋玲 姚庆宇 +4 位作者 薛钧升 李思 张敬 刘东阳 周田彦 《药学学报》 CAS CSCD 北大核心 2021年第2期538-544,共7页
M701为抗分化簇3/表面上皮细胞黏附因子(cluster of differentiation 3/epithelial cell adhesion molecule,CD3/EpCAM)的双特异性抗体,拟用于治疗癌细胞腹腔转移引起的恶性腹水。本研究应用群体模型方法,构建M701在人结肠癌异种移植小... M701为抗分化簇3/表面上皮细胞黏附因子(cluster of differentiation 3/epithelial cell adhesion molecule,CD3/EpCAM)的双特异性抗体,拟用于治疗癌细胞腹腔转移引起的恶性腹水。本研究应用群体模型方法,构建M701在人结肠癌异种移植小鼠中的药动学/药效学(pharmacokinetic/pharmacodynamics,PK/PD)模型,定量描述和预测M701在人结肠癌异种移植小鼠中的抗肿瘤作用。基于人结肠癌异种移植小鼠单次给药后不同时间点血浆药物浓度,构建PK模型。基于人结肠癌异种移植小鼠(32只)在33天的肿瘤体积随时间变化曲线,构建对照组及给药组结肠癌小鼠的肿瘤生长模型。所有动物实验均严格遵守武汉友芝友公司动物实验福利规定。使用非线性混合效应模型(nonlinear mixed-effect modeling,NONMEM)构建M701药动学和肿瘤生长模型,并且进行模型验证评价。基于PK/PD模型,仿真不同给药方案下M701对肿瘤体积生长的抑制效果。选择二室模型描述M701静脉给药后人结肠癌异种移植小鼠体内的PK特征。使用Simeoni串联转移隔室模型描述在人结肠癌异种移植小鼠中M701药物浓度与肿瘤生长抑制之间的关系。肿瘤生长模型预测参数包括肿瘤生长特征参数λ0(0.212 d^(-1))、λ1(0.0447 cm3·d^(-1))、药物效应参数k2(0.0715 mL·ng^(-1)·d^(-1))及肿瘤凋亡动力学参数k1(2×10^(-5)d^(-1))。可视化预测检测(visual predictive check,VPC)结果显示,PK模型及肿瘤生长模型的预测结果均能很好地拟合观测数据。PK/PD模型仿真结果显示,每6日静脉注射0.5 mg·kg^(-1)及每3日静脉注射0.25 mg·kg^(-1)可有效抑制小鼠肿瘤体积生长。本研究成功构建了M701在人结肠癌异种移植小鼠中的PK/PD模型,定量研究了M701在人结肠癌异种移植小鼠的抗肿瘤效果,为新化合物M701的进一步药物研发提供参考。 展开更多
关键词 双特异性抗体 人结肠癌异种移植小鼠 药动学/药效学模型 模拟与仿真
原文传递
Development and validation of a sensitive LC/MS-MS method for the determination of letrozole in nude mice plasma and its application to a pharmacokinetic study 被引量:2
6
作者 Junsheng Xue Qingyu Yao +5 位作者 Jian Li Wenjun Chen Hong Su Xiuyun Tian Chunyi Hao Tianyan Zhou 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2018年第10期665-674,共10页
A sensitive,rapid and simple liquid chromatography-tandem mass spectrometric(LC-MS/MS) method was developed and validated for the determination of letrozole(LTZ) in nude mouse plasma in the current study,which was... A sensitive,rapid and simple liquid chromatography-tandem mass spectrometric(LC-MS/MS) method was developed and validated for the determination of letrozole(LTZ) in nude mouse plasma in the current study,which was successfully applied to a pharmacokinetic study.Using anastrozole as internal standard(IS),plasma samples went through a one-step protein precipitation with acetonitrile before determination.The analyte and IS were analyzed on a reversed-phase ZORBAX-SB-C18 column(4.6 mm×250 mm,5 μm) with an isocratic mobile phase consisting of acetonitrile and water containing 0.1% formic acid(v/v) at a flow rate of 1.0 mL/min.The analyte and IS were detected by a triple-quadrupole tandem mass spectrometer,and electrospray and multiple reaction monitoring(MRM) were employed to select LTZ at m/z 286.4/217.1 and IS at m/z 294.1/225.3 simultaneously in the positive ion mode.The calibration curve showed good linearity ranging from 0.8–2000.0 ng/mL(r〉0.99).The intra-day and inter-day precisions of LTZ were 4.0%–8.4%,with an accuracy of 98.6%–104.9%.Using this method,we successfully characterized the pharmacokinetics(PK) of LTZ by a one-compartment model with first-order absorption in female BALB/c nude mice. 展开更多
关键词 LC-MS/MS LETROZOLE Nude mice PHARMACOKINETICS
原文传递
QAP21 reduces stemness and mobility of metastatic breast cancer cells involving D1DR activation 被引量:1
7
作者 Ling Yong Ye Yao +6 位作者 Mengyi Han Xiaoxue Yan Qingyu Yao Yuchen Guo Junsheng Xue Guoshu Chen Tianyan Zhou 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2021年第4期289-305,共17页
Breast cancer is the second leading cause of cancer death in women mainly due to metastasis,which is closely related to cancer stemness.Evidence has shown that cancer stem-like cells(CSCs),which are responsible for ca... Breast cancer is the second leading cause of cancer death in women mainly due to metastasis,which is closely related to cancer stemness.Evidence has shown that cancer stem-like cells(CSCs),which are responsible for cancer stemness,can be decreased by activating dopamine D1 receptor(D1 DR).In the present study,we aimed to explore the pharmacological effects as well as the underlying mechanisms of QAP21,a newly synthesized compound that can be orally administered,in metastatic breast cancer cells.Our results showed that QAP21 dose-dependently inhibited the ability of colony formation in 4 T1 and MDA-MB-231 cells.Cell mobility,including cell migration and invasion,was also remarkably inhibited.Besides,QAP21 significantly inhibited mammosphere formation and decreased CSC proportion,indicating reduced cancer stemness.We further verified that the nuclear factor-kappa B(NF-κB)/Akt/epithelial-mesenchymal transition(EMT)pathway was markedly impacted by QAP21 treatment.Moreover,QAP21 up-regulated the expressions of D1 DR and its second messengers,including cAMP and cGMP,which can be increased when D1 DR is activated.SCH 23390,a specific D1 DR antagonist,partially or completely reversed the above-mentioned effects of QAP21,indicating that D1 DR activation might be involved in the underlying mechanism of QAP21.In summary,QAP21 effectively reduced breast cancer stemness and cell mobility,indicating its potential use for metastatic breast cancer therapy. 展开更多
关键词 Metastatic breast cancer Dopamine D1 receptor Cancer stemness Cell mobility QAP21
原文传递
Dopamine increases the anti-cancer efficacy of sunitinib in the treatment of pancreatic cancer 被引量:1
8
作者 Junsheng Xue Siyuan Wang +6 位作者 Fangran Hao Xiuyun Tian Hong Su Liang Yang Qiming An Chunyi Hao Tianyan Zhou 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2020年第10期689-700,共12页
Sunitinib(SUN)is a multi-targeted receptor tyrosine kinase inhibitor(TKI)that may lead to drug resistance and metastasis because of increased cancer stem-like cells(CSCs)due to the induction of hypoxia.Our group has p... Sunitinib(SUN)is a multi-targeted receptor tyrosine kinase inhibitor(TKI)that may lead to drug resistance and metastasis because of increased cancer stem-like cells(CSCs)due to the induction of hypoxia.Our group has proved that dopamine(DA)can specifically reduce CSC frequency and enhance the response of SUN in drug-resistant breast cancerand non-small cell lung cancer(NSCLC).In this study,DA and SUN combination therapy was investigated in the treatment of pancreatic cancer,a malignant tumor with high mortality rate and very limited therapies.The cytotoxicity assay,clone formation assay and wound healing assay in two pancreatic cancer cell line PANC-1 and SW1990 showed that DA could significantly increase the effect of SUN on cell survival,clone formation ability and migration ability.Besides,SW1990 cell-derived xenograft model and a pancreatic cancer patient-derived xenograft(PDX)model were constructed,further proving that DA could increase the in vivo anti-tumor efficacy of SUN,and could be reversed by SCH23390,a D1 dopamine receptor(D1DR)antagonist.Moreover,the CSC frequency of the combination groups was lower than the control groups or SUN monotherapy groups.In addition,the body weight,H&E staining and blood routine test results showed that the combination therapy was safe.In summary,DA and SUN combination therapy could be a promising strategy for the treatment of pancreatic cancer. 展开更多
关键词 SUNITINIB DOPAMINE Cancer stem-like cell Combination therapy Pancreatic cancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部